文献速递血栓与止血造血干细胞移植与细胞治疗

重组人凝血因子Ⅶa治疗16例血液病合并中重度出血的临床疗效

[Clinical efficacy of recombinant activated factor Ⅶ a for 16 hematonosis with moderate or severe bleeding].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2017-01-01

回顾性分析2013年5月至2016年5月16例合并中重度出血的血液病患者,非移植组与移植组各8例,应用重组人凝血因子Ⅶa(rFⅦa)治疗。非移植组止血显效率75.0%(6/8),移植组37.5%(3/8);显效组中位OS 268.0天,无效组24.0天。结论认为rFⅦa有一定止血疗效,显效者生存率更高。

要点

  • 非移植组rFⅦa止血显效率75.0%(6/8),移植组37.5%(3/8)。
  • 16例中显效9例、无效7例,显效组中位OS 268.0天,无效组24.0天。
  • allo-HSCT后肠道aGVHD肠出血观察组(6例)与对照组(15例)中位OS分别为25.5天和20.0天。

核心结论

  • 血液病患者尤其是allo-HSCT患者出血相关死亡率高,rFⅦa治疗有一定止血疗效。
  • 显效组患者OS率较无效组高。
  • allo-HSCT后肠道出血患者采用rFⅦa治疗止血效果不佳的原因可能与移植后导致出血的并发症控制不佳有关。

研究设计与样本

  • 回顾性分析2013年5月至2016年5月住院治疗的16例合并中至重度出血的血液病患者,非移植组及移植组各8例。
  • 两组患者应用rFⅦa的用法、用量无明显差异。
  • 以同期15例allo-HSCT后发生肠道aGVHD肠出血患者为对照组(未应用rFⅦa)。

主要发现

  • 非移植组与移植组rFⅦa止血显效率分别为75.0%(6/8)和37.5%(3/8),显效中位时间分别为38.5小时和63.0小时。
  • 非移植组与移植组中位OS分别为201.0天和29.0天,OS率分别为50.0%(4/8)和25.0%(2/8)。
  • 非移植组与移植组出血相关死亡率分别为50.0%(2/4)和83.3%(5/6)。
  • 16例中显效9例、无效7例,显效组与无效组中位OS分别为268.0天和24.0天,OS率分别为66.7%(6/9)和0(0/7)。
  • 肠道aGVHD合并肠出血患者中,观察组(6例)与对照组(15例)中位OS分别为25.5天和20.0天。

临床怎么用

  • 作者认为血液病患者尤其是allo-HSCT患者出血相关死亡率高,rFⅦa治疗有一定止血疗效。
  • 作者认为显效组患者OS率较无效组高。
  • 作者认为allo-HSCT后肠道出血患者采用rFⅦa治疗止血效果不佳的原因可能与移植后导致出血的并发症控制不佳有关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the efficacy of recombinant activated factor Ⅶ a (rF Ⅶ a) on hematonosis with moderate or severe bleeding signs. Methods: Of total 16 cases with rF Ⅶ a treatment from May 2013 to May 2016, 8 cases received allogeneic hematopoietic stem cells transplantation (allo-HSCT) and the other were non-transplantation patients. In two groups, there was no significant difference on rF Ⅶ a usage and dosage. 15 patients with acute graft-versus-host disease (aGVHD) after allo-HSCT were control group (without rF Ⅶ a) . Results: ①The total response rate was 75.0% (6/8) in non-transplantation group and 37.5% (3/8) in transplantation group, respectively. Median interval for hemorrhage stop was 38.5 hours in non-transplantation group and 63.0 hours in transplantation group. The median overall survival (OS) was 201.0 and 29.0 days for non-transplantation group and transplantation group, respectively, and the OS rate was 50.0% (4/8) and 25.0% (2/8) , respectively. The bleeding-related mortality rate was 50.0% (2/4) and 83.3% (5/6) , respectively. ②Of the 16 cases, 9 showed response to rF Ⅶ a treatment and the other 7 cases'bleeding signs did not alleviate. The median OS was 268.0 in 9 cases with response and 24.0 days in 7 cases without response, respectively. ③In patients with intestinal aGVHD complicated with intestinal hemorrhage, the median OS of observation group (n=6) and control group (n=15) were 25.5 days and 20.0 days, respectively. Conclusion: Patients with hematological diseases, especially patients after allo-HSCT, had high bleeding-related mortality, and rFⅦa therapy had a obvious hemostatic efficacy. The survival rate of patients with response was higher than that of cases without response. The causes of poor hemostasis efficacy of rF Ⅶ a therapy were associated with unsatisfactory control of complications in patients with intestinal bleeding after allo-HSCT. 目的:观察重组人凝血因子Ⅶa(rFⅦa)对血液病及其异基因造血干细胞移植(allo-HSCT)术后出血患者的止血疗效。方法:以2013年5月至2016年5月住院治疗的16例合并中至重度出血的血液病患者为观察对象,非移植组及移植组患者各8例,两组患者应用rFⅦa的用法、用量无明显差异。同时,以同期15例allo-HSCT后发生肠道急性移植物抗宿主病(aGVHD)肠出血患者为对照组(未应用rFⅦa),将其与allo-HSCT后肠道aGVHD肠出血应用rFⅦa患者进行生存比较,总结患者应用rFⅦa治疗的临床疗效。结果: ①非移植组与移植组患者中,rFⅦa止血显效率分别为75.0%(6/8)和37.5%(3/8),显效中位时间分别为38.5和63.0 h,中位总生存(OS)时间分别为201.0和29.0 d,OS率分别为50.0%(4/8)和25.0%(2/8),出血相关死亡率分别为50.0%(2/4)和83.3%(5/6)。②16例患者中显效者9例,无效者7例,显效组与无效组患者中,中位OS时间分别为268.0和24.0 d,OS率分别为66.7%(6/9)和0(0/7)。③同期肠道aGVHD合并肠出血患者,观察组(6例)与对照组(15例)患者的中位OS时间分别为25.5和20.0 d。结论:血液病患者尤其是allo-HSCT患者出血相关死亡率高,rFⅦa治疗有一定止血疗效;显效组患者OS率较无效组高;allo-HSCT后肠道出血患者采用rFⅦa治疗止血效果不佳的原因可能与移植后导致出血的并发症控制不佳有关。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yang F, Kong LJ, Hu JW, et al. [Clinical efficacy of recombinant activated factor Ⅶ a for 16 hematonosis with moderate or severe bleeding]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28395445. doi:10.3760/cma.j.issn.0253-2727.2017.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。